WX390 plus Toripalimab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two investigational drugs, WX390 and Toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that standard treatments have failed or no standard treatment exists.
- You are in good enough health to perform daily activities (ECOG 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You have not had cancer therapy or major surgery in the last 30 days.
- You do not have active infections like HIV, hepatitis B or C, or serious ongoing infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called WX390 for people whose advanced solid tumors have not responded to standard treatments. The study aims to see if WX390 can help shrink or slow the growth of these tumors.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
This trial tests a combination of an experimental pill (WX390) and an immunotherapy drug (Toripalimab) for a specific type of cervical cancer that has an STK11 gene change. It aims to see if this combination can shrink tumors or slow the cancer.
This study tests a new combination of two drugs for cervical cancer that has returned or spread and did not get better with platinum-based chemotherapy. It aims to see if the combination works better than the standard treatment options.
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
This trial tests a new drug (LM-108) combined with an existing immunotherapy (toripalimab) for people with advanced cancers that have a specific genetic feature (MSI-H or dMMR). The goal is to see if this combination can help when previous immunotherapy hasn't worked.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.